替诺福韦治疗慢性乙型肝炎患者疗效及安全性分析*

doi:10.3969/j.issn.1672-5069.2018.06.006

摘要/Abstract

摘要： 目的观察比较应用替诺福韦（TDF）和恩替卡韦（ETV）治疗慢性乙型肝炎（CHB）患者的疗效和安全性。方法 2015年1月~2016年12月我中心收治的初始治疗的CHB患者60例,采用随机数字表法将患者分为两组,每组30例,分别给予TDF或ETV治疗,观察96 w,比较两组血清HBV DNA和丙氨酸氨基转移酶（ALT）水平和阴转率或复常率及不良反应发生情况。结果在治疗前、治疗第12 w、24 w、48 w、72 w和96 w,TDF治疗组患者血清HBV DNA水平分别为（7.5±0.9）lg IU/mL、（1.7±1.4）lg IU/mL、（1.1±1.0）lg IU/mL、（1.0±0.8）lg IU/mL、（0.7±0.6）lg IU/mL和（0.6±0.5）lg IU/mL,ETV治疗组则分别为（6.8±1.5）lg IU/mL、（2.1±1.1）lg IU/mL、（1.8±1.1）lg IU/mL、（1.0±0.7）lg IU/mL、（0.8±0.8）lg IU/mL和（0.9±0.8）lg IU/mL,在治疗24 w前,TDF治疗组血清HBV DNA水平显著低于ETV治疗组,差异具有统计学意义（P<0.05）; TDF治疗组血清ALT水平分别为（205.8±23.8） U/L、（80.7±8.6） U/L、（49.7±12.5）U/L、（46.2±6.7）U/L、（42.5±6.5）U/L和（41.8±2.4）U/L,ETV治疗组则分别为（199.0±25.9） U/L、（99.8±11.0）U/L、（59.3±9.4）U/L、（53.9±8.8）U/L、（44.62±7.4）U/L和（42.7±4.5）U/L,在治疗24 w前,TDF组血清ALT水平显著低于ETV组（P<0.05）;在治疗第12 w、24 w、48 w、72 w和96 w,TDF组病毒学应答率分别为50.0%、70.0%、73.3%、80.0%和96.7%,而ETV组则分别为23.3%、56.7%、60.0%、70.0%和93.3%,在治疗12 w时,TDF组显著高于ETV组（P<0.05）;TDF组血清ALT复常率分别为63.3%、96.7%、96.7%、100.0%和100.0%,ETV组则分别为50.0%、86.7%、96.7%、96.7%和100.0%,两组无统计学差异（P>0.05）。结论在当前情况下,应用TDF或ETV任一药物治疗CHB初治患者,均有很好的近期疗效,TDF显示出更早的病毒学应答率,值得进一步观察。

关键词: 慢性乙型肝炎, 替诺福韦, 恩替卡韦, 治疗, 应答

Abstract: Objective To observe the efficacy and safety of tenofovir（TDF） in the treatment of patients with chronic hepatitis B（CHB）. Methods Sixty naive patients with CHB were enrolled in our hospital between January 2015 and December 2016,and were randomly divided into two groups,with 30 patients in each group. 30 patients with CHB were given TDF and the other 30 patients with CHB were given entecavir （ETV） treatment for 96 weeks. Serum alanine aminotransferase （ALT） and HBV DNA levels,as well as virological and biochemical response rates were compared between the two groups. Results Before treatment and at the end of 12 w,24 w,48 w,72 w and 96 w of treatment,serum HBV DNA levels in TDF-treated group were（7.5±0.9） lg IU/mL,（1.7±1.4）lg IU/mL,（1.1±1.0） lg IU/mL,（1.0±0.8） lg IU/mL,（0.7±0.6） lg IU/mL and（0.6±0.5） lg IU/mL,and in ETV-treated group were （6.8±1.5） lg IU/mL,（2.1±1.1） lg IU/mL,（1.8±1.1） lg IU/mL,（1.0±0.7） lgIU/mL,（0.8±0.8） lg IU/mL and （0.9±0.8） lg IU/mL,suggesting that at the first 24 w treatment,serum HBV DNA levels in TDF-treated group were significantly lower than in ETV-treated group （P<0.05）;serum ALT levels in TDF-treated group were （205.8±23.8） U/L,（80.7±8.6） U/L,（49.7±12.5） U/L,（46.2±6.7） U/L,（42.5±6.5） U/L and（41.8±2.4） U/L,and in ETV-treated group were （199.0±25.9） U/L,（99.8±11.0） U/L,（59.3±9.4） U/L,（53.9±8.8） U/L,（44.62±7.4） U/L and （42.7±4.5） U/L,respectively,showing than at the first 24 w,serum ALT levels in TDF-treated group decreased more obviously than in ETV-treated group （P<0.05）;at the end of 12 w,24 w,48 w,72 w and 96 w,the virologic response rates in TDF-treated group were 50.0%,70.0%,73.3%,80.0% and 96.7%,while in ETV-treated group were 23.3%（P<0.05）,56.7%,60.0%,70.0% and 93.3%,respectively;serum ALT normalization rates in TDF-treated group were 63.3%,96.7%,96.7%,100.0% and 100.0%,while in ETV-treated group were 50.0%,86.7%,96.7%,96.7% and 100.0%,showing no significantly different between the two groups （P>0.05）. Conclusion Both TDF and ETV might be the optimal option for treatment of naive patients with CHB at present, showing promising efficacy and good safety,which worth further and long-term investigation.

Key words: Chronic hepatitis B, Tenofovir, Entecavir, Therapy, Response

王耀峰. 替诺福韦治疗慢性乙型肝炎患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 847-850.

Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.

参考文献

[1] Wu CY,Lin JT,Ho HJ,et al.Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B:a nationwide cohort study. Gastroenterology,2014,147(1):143-151.
[2] Gurbuzel M,Saygi G,Ozyigit F,et al.Effect of the number of portal area on modified histological activity index of viral hepatitis and histological findings. Niger J Clin Pract,2013,17(1):56-61.
[3] Yapali S,Talaat N,Fontana RJ,et al.Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol,2015,13(1):193-201.
[4] 邓卫平,马德强,郑红梅,等. 恩替卡韦联合百令胶囊治疗对干扰素α-2b无应答的HBeAg阳性的慢性乙型肝炎患者疗效研究. 实用肝脏病杂志,2018,21(1):110-111.
[5] Ku YI,Sang KO,Woong PJ,et al.The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. Clin Mol Hepatol,2015,21(1):32-40.
[6] Lim YS.Management of antiviral resistance in chronic hepatitis B. Gut Liver,2017,11(2):189-195.
[7] Maratea D,Fadda V,Trippoli S,et al.Letter:first-line monotherapies for chronic hepatitis B-indirect comparison between entecavir and tenofovir. Aliment Pharmacol Ther,2013,37(5):584.
[8] Jin BX,Zhang YH,Jin WJ,et al.MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Sci Rep,2015(5):15026.
[9] Komatsu H,Inui A,Murano T,et al.Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection,and infection using chimeric mice. BMC Res Notes,2015,8(1):366.
[10] Li YF,Hu NS,Tian XB,et al.Effect of daily milk supplementation on serum and umbilical cord blood folic acid concentrations in pregnant Han and Mongolian women and birth characteristics in China. Asia Pac J Clin Nutr,2014,23(4):567-574.
[11] Nunen ABV,Hansen BE,Suh DJ,et al.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut,2003,52(3):420-424.
[12] 潘静,陆伦根. 核苷(酸)类似物初始治疗慢性乙型肝炎患者疗效和安全性的网络Meta分析. 实用肝脏病杂志,2017,20(1):29-33.
[13] Gomesgouvêa MS,Ferreira AC,Teixeira R,et al.HBV carrying drug-resistance mutations in chronically infected treatment-naive patients. Antivir Ther,2015,20(4):385-387.
[14] Boudreau DM,Arterburn D,Bogart A,et al.Influence of body mass index on the choice of therapy for depression and follow-up care. Obesity (Silver Spring),2013,21(3):E303.
[15] 郭立杰,王艳,王敏,等. 国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效观察. 实用肝脏病杂志,2017,20(2):226-227.
[16] Chang KC,Wu JF,Hsu HY,et al.Entecavir treatment in children and adolescents with chronic hepatitis B virus infection. Pediatr Neonatol,2016,57(5):390-395.
[17] Ruggeri M,Basile M,Coretti S,et al.Economic analysis and budget impact of tenofovir and entecavir in the first-line treatment of hepatitis B virus in Italy. Appl Health Econ Health Policy,2017,15:1-12.
[18] Okada M,Enomoto M,Kawada N,et al.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol,2017,11(12):1-10.
[19] 徐勇,冯继红,李荣宽,等. 不同核苷(酸)类似物治疗慢性乙型肝炎患者对eGFR的影响. 实用肝脏病杂志,2018,21(1):50-53.
[20] Sadler MD,Lee SS.Treatment of HBeAg+ chronic hepatitis B is tenofovir truly superior to entecavir. Aliment Pharmacol Ther,2014,39(11):1339.

替诺福韦治疗慢性乙型肝炎患者疗效及安全性分析^*

Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[5]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[6]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[7]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[8]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[9]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[10]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[13]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[14]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[15]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.